About the Company
Mirus Bio was founded in 1995 by three University of Wisconsin scientists, Drs. Jon A. Wolff, Vladimir Budker, and James E. Hagstrom, all established leaders in the field of gene delivery. The company started with two ambitious goals: first, to develop and manufacture the most efficient in vitro transfection reagents available; and second, to develop the first nonviral, self-assembling complexes (“artificial viruses”) to be used to deliver genes and RNAs in vivo for therapeutic applications.
In 1995, Mirus Bio scientists developed the formulation that led to the products known as TransIT®-LT1 and FuGENE® 6 Transfection Reagents (Mirus Bio extended a license to Roche to sell FuGENE 6). TransIT-LT1 was the first lipopolyplex transfection reagent to provide both high efficiency and low toxicity (LT) DNA delivery to cells. This has proven to be the transfection formulation of choice for a generation of scientists.
In 2006 Mirus Bio scientists developed the first polymer-based, self-assembling nanoparticles, also known as DPCs—Dynamic PolyConjugates™, which facilitate highly efficient suppression of gene expression in mammals. This breakthrough technology represents the future of therapeutic RNA interference and led to the purchase of Mirus’ Therapeutic division by Roche Pharmaceuticals in 2008. The Products division of Mirus remains a privately held company, Mirus Bio.
Our initial goals continue to shape the direction of the company. Mirus Bio remains focused on the development and sale of novel in vitro transfection products for use by researchers worldwide. Most recent research efforts have led to the development of TransIT-2020, TransIT-PRO® and Ingenio®, which represent the most advanced products to date for broad-spectrum DNA transfection, protein production, and electroporation, respectively.